SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.

Already have an account? Log in here
RETURN TO HOME
$0
Autologous, CAR-T

New Gilead KITE-222 (CLL-1 CAR-T) Ph1 Trial in R/R AML Posted

Here is a brief preview of this blast: On Tuesday, March 9, a new Gilead (Kite) sponsored Ph1 trial was observed on CT.gov for a first-in-human study of KITE-222 (autologous CLL-1 CAR-T) in r/r acute myeloid leukemia (AML). Below, Celltelligence provides insights on the significance of Gilead expanding their pipeline into the AML setting and the potential competitors within the space.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.